The vice president for Medical Affairs discusses the recent Chindex Internationa merger, the challenges and opportunities that the company faces to meet the need for more private health care, as the central government ramps up spending and attitudes toward health insurance and medical incentives change.

It currently costs about $10 million to sequence the whole human genome. Reducing the cost to $100,000 will enable experimentation that can elucidate genetic contributions to major diseases. By cutting the cost to $1,000 or less, NABsys Inc. hopes to make genome sequencing an integral part of every individual's routine medical care.

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.

Summarizing the month in European dealmaking.